ProMIS Neurosciences Inc. · NASDAQ:PMN
ProMIS Neurosciences — Investor Presentation (November 2026)
31 slides from ProMIS Neurosciences's investor presentation, Nov 12, 2026
Slide 1: Targeting underlying causes of neurodegenerative diseases
Targeting underlying causes of neurodegenerative diseases
Slide 2: Forward-Looking Statements & Disclaimers
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential L E G A L D I S C L O S U R E S Forward-Looking Statements & Disclaimers This slide deck may contain certain forward-looking information and “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Se
Slide 3: Who we are: clinical-stage biotech targeting misfolded proteins
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential W H O W E A R E 3 A clinical-stage biotech targeting the misfolded proteins that drive neurodegenerative disease Our pipeline of antibodies and vaccines are designed to selectively target the specific, disease-causing misfolded forms of pro
Slide 4: The problem: Alzheimer's scale
T H E P R O B L E M 7.4 million Americans are living with Alzheimer’s today, and that number could nearly double to 13.8M by 2060 1 in 9 Americans age 65 and older has Alzheimer’s Each one is a parent, a spouse or a friend losing memory, independence and the ability to recognize the people they love
Slide 5: Anti-amyloid plaque therapies sell ~$1.4B a year despite safety risks
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Anti-amyloid plaque therapies already sell ~$1.4B a year despite significant safety risks and a boxed warning 5 Clinical Benefit (CDR-SB) Boxed Warning: ARIA Annual Sales Ests. (1) Leqembi (lecanemab) Approved 2023 Adjusted Mean Change from
Slide 6: ~95% of eligible U.S. patients remain untreated
An estimated ~95% of eligible U.S. patients remain untreated, facing safety, access and cost barriers M A R K E T O P P O R T U N I T Y 6 Market opportunity ~1.26M are early-stage and label-eligible today(2) ~95% untreated (~1.2M patients) ~5% treated (~63K patients)(2) How a Top obstacles to curren
Slide 7: Lead Clinical Candidate PMN310 in Alzheimer's Disease
Lead Clinical Candidate PMN310 in Alzheimer’s Disease Selectivity for Toxic Aβ Oligomers
Slide 8: Neutralizing toxic AβOs upstream can reduce downstream damage
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Neutralizing toxic AβOs upstream can reduce downstream damage 8 1.The Amyloid Cascade Hypothesis. Castellani, Rudy J. et al. The American Journal of Pathology, Volume 195, Issue 11, Nov 2025 2.Cline EN, et al. The Amyloid-β Oligomer Hypothe
Slide 9: Toxic Aβ oligomers: low abundance, high toxicity, the target of PMN310
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Toxic Aβ oligomers: low abundance, high toxicity, the target of PMN310 in Alzheimer’s disease 9 ILLUSTRATIVE RELATIVE ABUNDANCE OF Aβ SPECIES1 1. 1. Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins:
Slide 10: EpiSelect computational platform for selective antibodies
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential EpiSelectTM computational platform allows for the generation of antibodies selective for toxic misfolded proteins 10 D I S C O V E R Y P L A T F O R M Normal protein (monomers) Misfolds Toxic oligomer Conformational epitope exposed EpiSelec
Slide 11: PMN310 is the only IgG1 mAb designed to solely target toxic Aβ oligomers
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential PMN310 is the only IgG1 mAb designed to solely target toxic amyloid-beta (Aβ) oligomers PMN310 (ProMIS) Phase 1b ongoing Lecanemab (Eisai) Approved Donanemab (Eli Lilly) Approved Sabirnetug (Acumen) Phase 2 Target binding Plaque binding is
Slide 12: PMN310 had undetectable plaque binding
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Plaque detection (no mAb) Amylo-Glo Staining with mAb Staining with mAb Isotype negative controls Test antibodies (fluorescence) (chromogenic) PMN310 was the only mAb tested with undetectable plaque binding through fluorescent and chromogen
Slide 13: Phase 1a SAD study met all objectives
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Healthy volunteers Randomized 3:1, PMN310:Placebo (N=8 per cohort) First subject dosed Nov. 2023 Dose 2.5 mg/kg (N = 6:2) Dose 5 mg/kg (N = 6:2) Dose 10 mg/kg (N = 6:2) Dose 20 mg/kg (N = 6:2) Dose 40 mg/kg (N = 6:2) PMN310 Placebo-Controll
Slide 14: PMN310 reduced Aβ oligomers in CSF in Phase 1a
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential T A R G E T E N G A G E M E N T PMN310 reduced Aβ oligomers in CSF in Phase 1a, measured directly by the sFIDA assay What it measures Aβ oligomer particles in CSF, the target of PMN310 How it works • Captures oligomers and detects them with
Slide 15: Dose-dependent reduction in CSF Aβ oligomer particles
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential A A I C 2 0 2 6 · P H A S E 1 a T A R G E T E N G A G E M E N T PMN310 produced a dose-dependent reduction in CSF Aβ oligomer particles Day 3 post-dose Day 29 post-dose First human evidence of Aβ oligomer target engagement by PMN310 • Relat
Slide 16: PRECISE-AD Interim Analysis Results
16 PRECISE-AD Interim Analysis Results Presented July 28, 2026 1 Demographics and Study Design 2 Safety Results 3 Biomarker Trends
Slide 17: PRECISE-AD: Phase 1b with FDA Fast Track
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential PRECISE-AD: Phase 1b with FDA Fast Track Randomized, double-blind, placebo-controlled multiple ascending dose study of PMN310 in early AD 17 T R I A L D E S I G N STUDY DESIGN · STAGGERED COHORTS · 12 MONTHS EACH 6-month interim blinded 12-
Slide 18: PRECISE-AD enrolled a representative AD population
T R I A L D E M O G R A P H I C S PRECISE-AD Enrolled a Representative AD Population, Including the Highest ARIA-Risk Patients WHY APOE4 MATTERS ✓ Representative population, including highest ARIA-risk patients Treatment options may open for ~15% of AD patients who are APOE4 homozygotes, the group c
Slide 19: Favorable safety data across key measures
I N T E R I M S A F E T Y · 6 - M O N T H B L I N D E D Favorable Safety Data, Observed Across Key Measures 6-month blinded interim · N = 144 dosed, 136 safety-evaluable · a representative population 0.0% ARIA-E The most severe treatment-driven form of ARIA No treatment-related serious AEs Across al
Slide 20: Cumulative ARIA-E over time: zero edema in first 6 months
T I M E - M A T C H E D S A F E T Y Cumulative ARIA-E Over Time: Zero Edema Observed in First 6 Months ARIA-E (the most serious ARIA type) has been observed to occur almost entirely in the first six months of dosing. Comparator ARIA-E plateaus after the first few months; rates are time-matched to pu
Slide 21: Cumulative total ARIA over time
T I M E - M A T C H E D S A F E T Y Cumulative Total ARIA Over Time: Blinded PRECISE-AD Data Tracks the Placebo Range Reported in Other Trials Approved anti-amyloids accrue ARIA steeply in the first months of dosing, with 90%+ of ARIA-E occurring in the first 6 months. Comparator rates are time-matc
Slide 22: PRECISE-AD Interim Biomarker Results
22 PRECISE-AD Interim Biomarker Results
Slide 23: Two tau biomarkers reported
B I O M A R K E R S R E P O R T E D Two tau biomarkers reported, both expected to rise without treatment 23 Plasma pTau217 BLOOD-BASED W HAT I T M EASURES Disease progression: a downstream marker of amyloid-positive AD pathology and tau pathway activation. I N UNTREATED PATI ENTS In untreated (place
Slide 24: Plasma pTau217 declined through Day 169
6 - M O N T H B L I N D E D A N A L Y S I S · P L A S M A PRECISE-AD INTERIM RESULTS: Plasma pTau217 declined steadily through Day 169 PRECISE-AD Mean % change from baseline over time -25 -20 -15 -10 -5 0 5 0 29 85 141 169 % change from baseline Study day Linear trend PRECISE-AD patients with a Day-
Slide 25: CSF MTBR-tau243 declined through Day 169
6 - M O N T H B L I N D E D A N A L Y S I S · C S F PRECISE-AD INTERIM RESULTS: CSF MTBR-tau243 declined through Day 169 PRECISE-AD Mean % change, screen → Day 169 -25 -20 -15 -10 -5 0 5 Screen Day 169 % change from baseline Timepoint PRECISE-AD: Patients with a Day-169 decline 62.5% 37.5% 0 20 40 6
Slide 26: Conclusion: a differentiated, precision approach to Alzheimer's
C O N C L U S I O N A Differentiated, Precision Approach to Alzheimer’s — With a Clear Path Forward PRECISE-AD’s blinded interim analysis shows favorable safety data and early, mechanism-consistent biomarker signals, supporting a differentiated approach for patients underserved by approved anti-amyl
Slide 27: Topline in Q1 2027 and the Path Forward
27 Topline in Q1 2027 and the Path Forward
Slide 28: Q1 2027 topline data target scenario
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential T O P L I N E · Q 1 2 0 2 7 Q1 2027 topline data aims to show a material shift in benefit-risk 28 Target scenario reflect management’s view on possible safety and directional efficacy signals and is not based on any review of clinical data
Slide 29: 2026 Strategic Priorities
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Q 1 Q 2 Q 3 Q 4 PRECISE-AD Phase 1b PMN310 in early AD — execute + complete Phase 1b Execution Subcutaneous PMN310 Accelerated SC formulation development SC formulation + PK/PD Registrational study prep PMN310 pivotal trial readiness Site a
Slide 30: Why ProMIS
W H Y P R O M I S Early PRECISE-AD signals support PMN310’s differentiated profile S U M M A R Y A potentially favorable and differentiated benefit-risk profile 12-month PRECISE-AD topline in Q1 2027, with cash runway through 2027 30 01 Novel precision targeting EpiSelect discovery platform, with a
Slide 31: For further information, contact
NASDAQ: PMN For further information, contact: info@promisneurosciences.com
ProMIS Neurosciences — Investor Presentation (November 2026) on 6ix